Nancy Whiting
Director/Board Member at CARIBOU BIOSCIENCES, INC.
Net worth: - $ as of 31/03/2024
Profile
Nancy C.
Whiting is currently the Chief Executive Officer & Director at Recludix Pharma, Inc., an Independent Director at Caribou Biosciences, Inc., and an Independent Director at Boundless Bio, Inc. Previously, she held positions as the President, Secretary & Director at Cascadian Therapeutics LLC and as the Executive VP-Strategy, Alliances & Communications at Seagen Inc. Dr. Whiting has a graduate degree from the University of Washington and an undergraduate degree from the University of British Columbia.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 20/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 | |
BOUNDLESS BIO INC.
-.--% | 28/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Nancy Whiting active positions
| Companies | Position | Start |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24/08/2021 |
| BOUNDLESS BIO, INC. | Director/Board Member | 02/10/2023 |
Recludix Pharma, Inc.
 Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Chief Executive Officer | 01/09/2021 |
Former positions of Nancy Whiting
| Companies | Position | End |
|---|---|---|
| CASCADIAN THERAPEUTICS INC (USA) | President | - |
| SEAGEN INC. | Public Communications Contact | - |
Training of Nancy Whiting
| University of Washington | Graduate Degree |
| University of British Columbia | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
| Boundless Bio, Inc. | |
Recludix Pharma, Inc.
Recludix Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Recludix Pharma, Inc. is a biotechnology company that develops platform approaches to discover potent and selective inhibitors of challenging protein targets. The company is based in San Diego, CA. The company was founded by Brian Hodous, Nicholas B. Lydon, Patrick P. Zarrinkar, Daniel K. Treiber. Nancy C. Whiting has been the CEO of the company since 2021. | Commercial Services |
- Stock Market
- Insiders
- Nancy Whiting
